Startseite Kongressberichte 2019 ESMO 2019 Lung Cancer, Mesothelioma & Head and Neck Cancer

Statements Solange Peters & Alessandra Curioni-Fontecedro (Highlights)

(The statements will be uploaded later in the day and week)

Papers mentioned:

NEJM: M.D. Hellmann and OthersNivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer


Rolf Stahel, et al.

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug



Our analysis provides further evidence of the importance of the volume of experience and the availability of a multidisciplinary organisation and research environment, as delivered by a comprehensive cancer centre, on the outcome of patients with all stages of NSCLC.


Head & Neck Cancer

Conclusions:  The combination of avelumab, cetuximab and RT is tolerable for pts with LA-SCCHN in the safety phase of this ongoing phase 3 trial and an approval to continue the trial was given by IDSMC.